1-4 of 4
Michael Dickinson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma

Gilles Salles, Stephen J. Schuster, Martin Dreyling, Luca Fischer, John Kuruvilla, Piers E. M. Patten, Bastian von Tresckow, Sonali M. Smith, Ana Jiménez-Ubieto, Keith L. Davis, Carla Anjos, Jufen Chu, Jie Zhang, Chiara Lobetti Bodoni, Catherine Thieblemont, Nathan H. Fowler, Michael Dickinson, Joaquin Martínez-López, Yucai Wang, Brian K. Link
Journal: Blood Advances
Blood Adv (2022) 6 (22): 5835–5843.
https://doi.org/10.1182/bloodadvances.2022008150
Published: 2022
Journal Articles

Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma

Clinical Trials & Observations
Ann-Marie E. Bröske, Koorosh Korfi, Anton Belousov, Sabine Wilson, Chia-Huey Ooi, Christopher R. Bolen, Marta Canamero, Enrique Gomez Alcaide, Ian James, Emily C. Piccione, David J. Carlile, Natalie Dimier, Pablo Umaña, Marina Bacac, Martin Weisser, Michael Dickinson
Journal: Blood Advances
Blood Adv (2022) 6 (3): 1025–1037.
https://doi.org/10.1182/bloodadvances.2021005954
Published: 2022
Includes: Supplemental data
Journal Articles

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

Clinical Trials & Observations
Pier Luigi Zinzani, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A. Johnson, Jose S. R. de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Michael Dickinson, Andrew McDonald, Muhit Özcan, Naohiro Sekiguchi, Ying Zhu, Monika Raut, Todd L. Saretsky, Akash Nahar, John Kuruvilla
Journal: Blood Advances
Blood Adv (2022) 6 (2): 590–599.
https://doi.org/10.1182/bloodadvances.2021004970
Published: 2022
Includes: Supplemental data
Journal Articles

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma

Clinical Trials & Observations
Michael Dickinson, Javier Briones, Alex F. Herrera, Eva González-Barca, Nilanjan Ghosh, Raul Cordoba, Sarah C. Rutherford, Eirini Bournazou, Emily Labriola-Tompkins, Izolda Franjkovic, Evelyne Chesne, Jurriaan Brouwer-Visser, Katharina Lechner, Barbara Brennan, Eveline Nüesch, Mark DeMario, Dominik Rüttinger, Martin Kornacker, Martin Hutchings
Journal: Blood Advances
Blood Adv (2021) 5 (22): 4762–4770.
https://doi.org/10.1182/bloodadvances.2021004619
Published: 2021
Includes: Supplemental data